Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians, scientists, and researchers working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines. Vaccines for Cancer Immunotherapy provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines.
- Introduces the feasible immunotherapeutic vaccines for patients with different types of cancer
- Presents the status of past and current vaccines for cancer treatment
- Considers advantages and disadvantages of different therapeutic cancer vaccines
- Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods
- Analyzes obstacles to development of therapeutic cancer vaccines
- Gives a view on future perspectives in the application of therapeutic cancer vaccines
Nima Rezaei, MD, PhD, is Professor of Clinical Immunology and Allergy at Tehran University of Medical Sciences, where he also serves as Associate Dean of International Affairs for the School of Medicine and Director of the Global Academic Program. He is Deputy President of the Research Center for Immunodeficiencies and holds an affiliated research appointment in the Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet, Sweden. He earned his MD from Tehran University of Medical Sciences and his PhD in Clinical Immunology and Human Genetics from the University of Sheffield, United Kingdom. His research addresses primary immunodeficiencies and translational immunology, with recent work extending into computational and AI-based approaches to immune profiling. He is the founder and President of the Universal Scientific Education and Research Network (USERN) and serves as co-editor of the Springer Nature series Advances in Experimental Medicine and Biology.
Mahsa Keshavarz-Fathi is a medical researcher and MD candidate at Tehran University of Medical Sciences (TUMS). She is also the managing director of the Cancer Immunology Project (CIP) and Breast Cancer Association (BrCA) undertaking and managing different research projects in the field of cancer treatment, cancer immunology and immunotherapy.
